Navigation Links
Gen-Probe to Webcast Presentation at the 29th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2011 at approximately 11:30 a.m. Pacific Time.  The presentation is scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at The webcast will be available for 30 days following the event.

About Gen-ProbeGen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to

Caution Regarding Forward-Looking StatementsAny statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-K, and all subsequent periodic filings.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.Contact:Paula IzidoroInvestor Relations858-410-8904

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash
2. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
3. Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments
4. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
5. Gen-Probe to Webcast Four Upcoming Investor Presentations
6. Gen-Probe to Webcast Two Upcoming Investor Presentations
7. Gen-Probe Completes Acquisition of Tepnel Life Sciences
8. Gen-Probe to Webcast Two Upcoming Investor Presentations
9. Gen-Probe Borrows $170 Million Under New Line of Credit
10. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
11. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
Post Your Comments:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):